NEXAVAR may cause birth defects or death of an unborn baby. Avoid becoming pregnant while taking NEXAVAR and for at least 2 weeks after stopping your treatment. Men and women should use birth control during and at least 2 weeks after NEXAVAR therapy. Call your doctor right away if you become pregnant. Do not breastfeed while taking NEXAVAR as this medication may be passed through breast milk. continue reading below »
Nexavar was analyzed in the largest study ever conducted in patients with advanced kidney cancer.1
This study of 903 patients showed that the growth and spread of cancer was slowed in people who received Nexavar compared with people who did not. Nexavar was proven to1,2:
Important Safety Information
Ask your doctor if treatment with Nexavar is right for you.Read more about:
References: 1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318. 2. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454-1463.